)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Perpetua Medical
Perpetua Medical (PERP) investor relations material
Perpetua Medical Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary21 Aug, 2026
Executive summary
Net sales for Q2 2026 rose 121% year-over-year to 5,963 KSEK, driven by the Spirotronic acquisition and growth at ES Medical.
Operating loss widened to -3,095 KSEK in Q2 2026 from -538 KSEK a year earlier, mainly due to higher expenses from acquisitions and product development.
Cash and cash equivalents at quarter-end were 16,828 KSEK, up from 5,989 KSEK last year.
The company is actively pursuing further acquisitions and developing proprietary products in its subsidiaries.
Financial highlights
Q2 2026 net revenue: 5,963 KSEK (Q2 2025: 2,700 KSEK); H1 2026 net sales: 10,943 KSEK (H1 2025: 5,927 KSEK).
Q2 2026 operating loss: -3,095 KSEK (Q2 2025: -538 KSEK); H1 2026 operating loss: -5,861 KSEK (H1 2025: -1,972 KSEK).
Q2 2026 EPS: -0.36 SEK (Q2 2025: -0.16 SEK); H1 2026 EPS: -0.69 SEK (H1 2025: -0.44 SEK).
Q2 2026 cash flow: -3,456 KSEK (Q2 2025: -1,224 KSEK); H1 2026 cash flow: 12,495 KSEK (H1 2025: -3,411 KSEK).
Equity at 30 June 2026: 25,467 KSEK (30 June 2025: 8,912 KSEK); equity ratio: 44% (55%).
Outlook and guidance
Management expects further growth through additional acquisitions and proprietary product launches.
Ongoing negotiations with several acquisition targets could result in near-term transactions.
ES Medical is preparing to launch its first proprietary product in H2 2026.
Spirotronic is targeting integration of its components into next-generation ventilators.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Perpetua Medical
- Revenue up 54% year-over-year, but operating loss widened; strong cash supports acquisition focus.PERP
Q1 2026 - Net sales doubled and operating income turned positive, supported by a major capital raise.PERPQ4 2025
- Q3 2025 delivered record revenue and profit, fueled by asset sales and the Spirotronic acquisition.PERPQ3 2025
- Q2 2025 sales up 165%, losses reduced, major acquisition and asset sale boost outlook.PERPQ2 2025
- First acquisition completed, losses reduced, and cost base lowered as strategic shift advances.PERPQ3 2024
- Operating loss narrowed, cash position strengthened, and acquisition strategy advanced.PERPQ2 2024
- Strong sales growth from ES-Medical offset by negative operating result and strategic realignment.PERPQ1 2025
- Q4 revenue jumped 62% on ES-Medical, with improved losses and strong cash flow.PERPQ4 2024
Next Perpetua Medical earnings date
Q3 202620 Nov, 2026
Perpetua Medical
Next Perpetua Medical earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Perpetua Medical AB (publ), formerly known as Pharmacolog i Uppsala AB, is a Swedish medical technology company that specializes in developing systems and solutions to optimize and ensure the correct use of injectable drugs. The company's offerings include products like the Pharmacolog Dashboard, which provides tools for generating reports and statistical analyses of validated pharmaceuticals, and WasteLog, a device designed to manage the workflow by analyzing the waste and returns of injectable controlled substances. These solutions are aimed at preventing medication errors and drug diversion. The company is headquartered in Uppsala, Sweden, and its shares are listed on Nasdaq First North Stockholm.